Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gore

Showing results (171-180 of 314) with videos related to

Pageof 32
Sort By:
British Journal of Cancer|January 1, 1997
Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology GroupsM E Gore, G Rustin, M Slevin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanomaA L Jones, M E O'Brien, A Lorentzos, et al.
Human Gene Therapy|May 1, 1994
Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumorsP M Patel, C L Flemming, C Fisher, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Differential responses to chemoimmunotherapy in patients with metastatic malignant melanomaP N Mainwaring, H Atkinson, J Chang, et al.
European Journal of Cancer. Part B, Oral Oncology|July 1, 1994
The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neckM O'Brien, J B Schofield, A Lorentzos, et al.
European Journal of Cancer. Part B, Oral Oncology|January 1, 1993
Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neckG Dadian, P G Riches, D C Henderson, et al.
Gynecologic Oncology|July 7, 2007
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trialsMichelle L Harrison, Martin E Gore, David Spriggs, et al.
Journal of Telemedicine and Telecare|June 26, 1998
Preliminary results from the Northern Ireland arms of the UK Multicentre Teledermatology Trial: is clinical management by realtime teledermatology possible?M A Loane, H E Gore, S E Bloomer, et al.
British Journal of Haematology|February 1, 1989
In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myelomaB C Millar, J B Bell, J A Maitland, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 6, 2001
Opportunistic infection prophylaxis in the women's interagency HIV study (WIHS)M Augenbraun, P Tarwater, R Greenblatt, et al.
Pageof 32

Showing results (171-180 of 314) with videos related to

Sort By:
Pageof 32
British Journal of Cancer|January 1, 1997
Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology GroupsM E Gore, G Rustin, M Slevin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanomaA L Jones, M E O'Brien, A Lorentzos, et al.
Human Gene Therapy|May 1, 1994
Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumorsP M Patel, C L Flemming, C Fisher, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Differential responses to chemoimmunotherapy in patients with metastatic malignant melanomaP N Mainwaring, H Atkinson, J Chang, et al.
European Journal of Cancer. Part B, Oral Oncology|July 1, 1994
The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neckM O'Brien, J B Schofield, A Lorentzos, et al.
European Journal of Cancer. Part B, Oral Oncology|January 1, 1993
Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neckG Dadian, P G Riches, D C Henderson, et al.
Gynecologic Oncology|July 7, 2007
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trialsMichelle L Harrison, Martin E Gore, David Spriggs, et al.
Journal of Telemedicine and Telecare|June 26, 1998
Preliminary results from the Northern Ireland arms of the UK Multicentre Teledermatology Trial: is clinical management by realtime teledermatology possible?M A Loane, H E Gore, S E Bloomer, et al.
British Journal of Haematology|February 1, 1989
In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myelomaB C Millar, J B Bell, J A Maitland, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 6, 2001
Opportunistic infection prophylaxis in the women's interagency HIV study (WIHS)M Augenbraun, P Tarwater, R Greenblatt, et al.
Pageof 32